 REDWOOD CITY, Calif., June 02, 2021 GLOBE NEWSWIRE -- Revolution Medicines, Inc. Nasdaq: RVMD, a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Goldman Sachs 42nd Annual Global Healthcare Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event. 